HC Wainwright & Co. Reiterates Buy on Insmed, Maintains $230 Price Target

Insmed Incorporated -2.69% Post

Insmed Incorporated

INSM

142.79

143.62

-2.69%

+0.58% Post
HC Wainwright & Co. analyst Andrew S. Fein reiterates Insmed (NASDAQ: INSM) with a Buy and maintains $230 price target.